Skip to main content

Market Overview

Taysha Gene's Epilepsy Candidate Shows Encouraging Action In Preclinical Studies

Share:
Taysha Gene's Epilepsy Candidate Shows Encouraging Action In Preclinical Studies
  • Taysha Gene Therapies Inc (NASDAQ: TSHA) announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy.
  • Data were shared at the American Epilepsy Society Annual Meeting.
  • In knockout mouse models of SLC13A5 deficiency, treatment with TSHA-105 resulted in normalized citrate levels, reduced seizure activity, and improved survival regardless of age. 
  • "These preclinical results suggest that TSHA-105 can demonstrate functional improvements with intervention at any age in a potentially safe and tolerable manner which would be expected to translate into a meaningful benefit to patients with SCL13A5 deficiency," said Suyash Prasad, Chief Medical Officer and Head of R&D Taysha. 
  • The Company plans to submit an IND/CTA filing in 2022.
  • Price Action: TSHA shares closed 10.04% higher at $14.25 during after-hours trading on Monday.
 

Related Articles (TSHA)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Health Care Small Cap Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com